Back in February, the US Council of Economic Advisers issued a white paper on drug pricing implying that other rich countries should stop “free riding” off American innovation by negotiating drug prices to unfairly low levels after the US fronts the research and development costs. Perhaps in response, President Trump recently announced a proposal to bring down US drug prices. But until the US corrects the structural flaws in its own healthcare system, these efforts are bound to fall short.
CGD Policy Blogs
- (-) Remove The Future of Global Health Procurement filter The Future of Global Health Procurement
- (-) Remove Health Technology Assessment filter Health Technology Assessment
November 13, 2018